| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| Other Sizes |
|
Purity: ≥98%
Mosapride Citrate (formerly AS-4370; TAK-370 citrate; AS-4370 citrate; TAK 370 citrate) is a novel, potent and selective gastroprokinetic agent that has been used in patients with upper gastrointestinal disorders. It has a selective 5HT4 agonistic effect. Mosapride is used to treat functional dyspepsia, irritable bowel syndrome, gastritis, and gastroesophageal reflux disease by speeding up gastric emptying throughout the entire gastrointestinal tract in humans.
| Targets |
5-HT4 Receptor
|
|---|---|
| ln Vitro |
Mosapride citrate (1-100 nM) crosses the proximal and distal water transit times and considerably lengthens the average length of proximal and distal constrictions in the guinea pig water body [3]. In human liver cells (HMC424, 478, and 493), mosapride citrate (869 ng/mL, 48 h) increases cytochrome P450 (CYP1A2, 2B6, and 3A4) sensing capacity[4].
|
| ln Vivo |
Mosapride citrate (0.3–3 mg/kg or 30 mg/kg, blocked) facilitates the emptying of the trajectory valve, and a dosage model is suggested. At a dose of 30 mg/kg, significant trajectory portal emptying was seen[5]. 0.25, 0.5, 0.75 mg/kg, pathway) in buffers can activate 5-HT4 receptors, which attenuate the effects of NSAID induction[6].
|
| Animal Protocol |
NSAID-induced experimental ulcer model
0.25, 0.5 , 0.75 mg/kg p.o |
| References | |
| Additional Infomation |
See also: Mosapride (annotation moved to).
|
| Molecular Formula |
C27H33CLFN3O10
|
|
|---|---|---|
| Molecular Weight |
614.02
|
|
| Exact Mass |
613.183
|
|
| Elemental Analysis |
C, 52.82; H, 5.42; Cl, 5.77; F, 3.09; N, 6.84; O, 26.06
|
|
| CAS # |
112885-42-4
|
|
| Related CAS # |
Mosapride; 112885-41-3; Mosapride citrate dihydrate; 636582-62-2
|
|
| PubChem CID |
119583
|
|
| Appearance |
White to off-white solid powder
|
|
| Boiling Point |
549.2ºC at 760mmHg
|
|
| Flash Point |
286ºC
|
|
| Vapour Pressure |
4.11E-12mmHg at 25°C
|
|
| LogP |
2.936
|
|
| Hydrogen Bond Donor Count |
6
|
|
| Hydrogen Bond Acceptor Count |
13
|
|
| Rotatable Bond Count |
12
|
|
| Heavy Atom Count |
42
|
|
| Complexity |
749
|
|
| Defined Atom Stereocenter Count |
0
|
|
| SMILES |
O=C(NCC1CN(CC2=CC=C(F)C=C2)CCO1)C3=CC(Cl)=C(N)C=C3OCC.O=C(CC(C(O)=O)(O)CC(O)=O)O
|
|
| InChi Key |
HUZTYZBFZKRPFG-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C21H25ClFN3O3.C6H8O7/c1-2-28-20-10-19(24)18(22)9-17(20)21(27)25-11-16-13-26(7-8-29-16)12-14-3-5-15(23)6-4-14;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-6,9-10,16H,2,7-8,11-13,24H2,1H3,(H,25,27);13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)
|
|
| Chemical Name |
4-amino-5-chloro-2-ethoxy-N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]benzamide;2-hydroxypropane-1,2,3-tricarboxylic acid
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.07 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6286 mL | 8.1431 mL | 16.2861 mL | |
| 5 mM | 0.3257 mL | 1.6286 mL | 3.2572 mL | |
| 10 mM | 0.1629 mL | 0.8143 mL | 1.6286 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT06156995 | Recruiting | Drug: Oral Mosapride Tablets Device: Deep Acupuncture at Zhongliao Point to Stimulate Sacral Nerve |
Constipation | Guoliang Wu | January 1, 2023 | Not Applicable |
| NCT05720442 | Not yet recruiting | Drug: Tangweian Recipe Drug: Mosapride Citrate |
Diabetic Gastroenteropathy | Guang'anmen Hospital of China Academy of Chinese Medical Sciences |
February 1, 2023 | Phase 1 Phase 2 |
| NCT02180334 | Completed | Drug: Mosapride citrate Drug: Linagliptin Drug: Acetaminophen (paracetamol) |
Diabetes Mellitus, Type 2 | Seoul National University Hospital |
July 2014 | Phase 4 |
| NCT02106130 | Completed | Drug: Rebamipide Drug: Mosapride citrate |
Healthy | lDong Pharmaceutical Co Ltd | May 2013 | Phase 1 |
| NCT01094847 | Completed | Drug: DWJ1252 | Bioequivalence | Daewoong Pharmaceutical Co. LTD. | April 2010 | Phase 1 |
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
